Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYongqiang WeiXWXiaolei WeiRFRu Feng

Discussion

Loading...

Member takes

Overview

Cohort study revealed BTK inhibitors improve progression-free survival, suggesting specific genomic factors impact outcomes in CLL patients.

Key Points

  • Btk inhibitors significantly improve progression-free survival rates, achieving 5-year rates of 80.7%.
  • Among 84 patients assessed, those with TP53 mutations showed markedly poorer outcomes, indicating the need for genetic profiling pre-treatment.
  • Cohort study assessed treatment adherence and outcomes regarding BTK inhibitors at a single center over 1.8 years follow-up.
  • This research highlights the importance of individualized risk stratification in optimizing treatment approaches for CLL.

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbfehttps://doi.org/10.1182/blood-2025-7421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A predictive model for treatment failure in CLL/SLL patients receiving BTK inhibitor: A multi-center retrospective study2025
  2. 2Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  3. 3Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  4. 4Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025
  5. 5Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators2025